Mazen Noureddin,Arun J Sanyal
Mazen Noureddin
Purpose of review: Advancing our understanding of the mechanisms that underlie NASH pathogenesis. Recent findings: Recent findings on N...
Mazen Noureddin,Arun J Sanyal
Mazen Noureddin
Purpose of review: Advancing our understanding of the mechanisms that underlie NASH pathogenesis. Recent findings: Recent findings on N...
Correction: The Role of Anticoagulation in Treating Portal Hypertension [0.03%]
关于抗凝在治疗门静脉高压作用中的纠正意见
Laura Turco,Filippo Schepis,Erica Villa
Laura Turco
[This corrects the article DOI: 10.1007/s11901-018-0406-x.].
Published Erratum
Current hepatology reports. 2018;17(4):511. DOI:10.1007/s11901-018-0443-5 2018
Correction: Assessment and Management of Sleep Disturbance in Cirrhosis [0.03%]
肝硬化患者睡眠障碍的评估和管理：纠正意见
Chiara Formentin,Maria Garrido,Sara Montagnese
Chiara Formentin
[This corrects the article DOI: 10.1007/s11901-018-0390-1.].
Published Erratum
Current hepatology reports. 2018;17(3):300. DOI:10.1007/s11901-018-0402-1 2018
The Use of Biologics in Patients with Inflammatory Bowel Disease and Primary Sclerosing Cholangitis [0.03%]
生物制剂在炎症性肠病和原发性硬化性胆管炎患者中的应用
Kate D Lynch,Satish Keshav,Roger W Chapman
Kate D Lynch
Purpose of review: Biologics are well established in the treatment of many immuno-inflammatory diseases including inflammatory bowel disease (IBD). However, although primary sclerosing cholangitis (PSC) is closely associa...
The impact of direct-acting antiviral therapy for hepatitis C on hepatocellular carcinoma risk [0.03%]
直接抗病毒疗法对丙型肝炎患者发生肝细胞癌风险的影响
Feng Su,George N Ioannou
Feng Su
Purpose of review: Direct-acting antiviral agents (DAAs) eradicate hepatitis C virus (HCV) infection in the majority of patients. We critically evaluated the impact of DAAs on hepatocellular carcinoma (HCC) risk, a major ...
Hans L Tillmann,Huiman X Barnhart,Jose Serrano et al.
Hans L Tillmann et al.
Purpose of review: Drug induced liver injury (DILI) is a complex diagnosis dominantly based of exclusion. Recent findings: Currently av...
Beware of HCV and HEV in Patients with Suspected Drug-Induced Liver Injury [0.03%]
谨防药物性肝损伤患者的HCV和HEV感染
Priya Grewal,Jawad Ahmad
Priya Grewal
Purpose of review-: Without a specific biomarker the diagnosis of drug-induced liver injury (DILI) relies on exclusion of other causes of liver injury. This review examines the importance of testing for hepatitis C (HCV) ...
Paul H Hayashi,Einar S Bjornsson
Paul H Hayashi
Purpose of the review: This review serves to update the reader on emerging data regarding a spectrum of drug-induced liver injury (DILI) outcomes that lie between complete resolution and acute liver failure. Such outcomes...
Small Esophageal Varices in Patients with Cirrhosis-Should We Treat Them? [0.03%]
肝硬化患者的小食管静脉曲张需要治疗吗？
Thomas Reiberger,Theresa Bucsics,Rafael Paternostro et al.
Thomas Reiberger et al.
Purpose of review: The natural history and classification systems of small varices (≤ 5 mm in diameter) in cirrhotic patients with portal hypertension are summarized. Studies that assessed the course of and therapeutic i...